Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study

Sun, Yan; Wu, Yi‐Long; Zhou, Caicun; Zhang, L.; Liu, X.-Y.; Yu, Shiying; Jiang, Guo Liang; Li, K.; Qin, Shukui; Ma, Shenglin; Han, Lu; Quinlivan, Mitchell; Orlando, Mauro; Zhang, X.-Q.

doi:10.1016/j.lungcan.2012.10.015

Cited by 25 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of which, 429 were excluded for their study design not fitting in with the including criteria and seven were excluded for the low quality. Finally, we included six studies (Hanna et al, 2004;Chen et al, 2008;Socinski et al, 2010;RodriguesPereira et al, 2011;Li et al, 2012;Sun et al, 2013), which containing 1, 414 patients. Of all the patients 927 (65.6%) were male.…”

Section: Search Results and Baseline Characteristics Of Included Trialsmentioning

confidence: 99%

“…All the six RCTs (Hanna et al, 2004;Chen et al, 2008;Socinski et al, 2010;Rodrigues-Pereira et al, 2011;Li et al, 2012;Sun et al, 2013) reported adequate generation of the allocation sequence, but none of the studies reported allocation concealment. Four (Hanna et al, 2004;Chen et (Hanna et al, 2004;Socinski et al, 2010;RodriguesPereira et al, 2011;Sun et al, 2013) did the intent-to-treat analysis, but two (Chen et al, 2008;Li et al, 2012) of them didn't report that.…”

Section: Quality Of Included Studiesmentioning

confidence: 99%

“…Four (Hanna et al, 2004;Chen et (Hanna et al, 2004;Socinski et al, 2010;RodriguesPereira et al, 2011;Sun et al, 2013) did the intent-to-treat analysis, but two (Chen et al, 2008;Li et al, 2012) of them didn't report that. All of the six RCTs (Hanna et al, 2004;Chen et al, 2008;Socinski et al, 2010;Rodrigues-Pereira et al, 2011;Li et al, 2012;Sun et al, 2013) reported the patients lost to follow-up in detail. Table 2 presents the specific information.…”

Section: Quality Of Included Studiesmentioning

confidence: 99%

“…All the six RCTs (Hanna et al, 2004;Chen et al, 2008;Socinski et al, 2010;Rodrigues-Pereira et al, 2011;Li et al, 2012;Sun et al, 2013) reported this outcome and 1, 400 patients were contained for this outcome (705 for pemetrexed group and 695 for docetaxel group). The rates in group pemetrexed and group docetaxel were 14.2% and 11.4% respectively.…”

Section: Overall Response Ratementioning

confidence: 99%

“…It was reported that there were more than 225 000 new cases of lung cancer and more than 160,000 deaths due to lung cancer in the United States in 2012 (Siegel et al, 2012). In China, the annual new cases are predicted to reach 1,000,000 by the year 2025 (Sun et al, 2013). Of all the lung cancer patients, non-small cell lung cancer (NSCLC) comprises approximately 80%, and the majority present with locally advanced or metastatic disease (Fathi et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis

Wei²,

Tian³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for non-small cell lung cancer (NSCLC). Materials and Methods: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. We limited the languages to English and Chinese. Two reviewers independently screened articles to identify eligible trials according to the inclusion and exclusion criteria and assessed the methodological quality of included trials, and then extracted data. The meta-analysis was performed using STATA12.0. Results: Six RCTs involving 1,414 patients were identified. We found that there was no statistically significant differences in overall response rate, survival time, progression-free survival, disease control rate, and 1-2yr survival rate (p>0.050) but it is worthy of mention that patients in the pemetrexed arms had significantly higher 3-yr survival rate (P=0.002). With regard to the grade 3 or 4 hematological toxicity, compared with docetaxel, pemetrexed led to lower rate of grade 3-4 febrile neutropenia, neutropenia, and leukocyts toxicity (p<0.001). There was no significant difference in anemia between the two arms (p=0.08). In addition, pemetrexed led to higher rate of grade 3-4 thrombocytopenia toxicity (p=0.03). As for the non-hematological toxicities, compared with docetaxel, pemetrexed group had lower rate of grade 3-4 diarrhea and alopecia. Conclusions: Pemetrexed was almost as effective as docetaxel in patients with advanced NSCLC. At the same time, pemetrexed might increase the 3-yr survival rate. As for safety, pemetrexed led to lower rate of grade 3-4 febrile neutropenia, neutropenia, leukocytes, diarrhea and alopecia toxicity. However, it was associated with a higher rate of grade 3-4 thrombocytopenia.

show abstract

Section: Search Results and Baseline Characteristics Of Included Trialsmentioning

confidence: 99%